FinancingRegulatory filing
What was reported
As previously disclosed, Lifeward Ltd. (the “Company”) entered into a securities purchase agreement (the “Prior SPA”) with Oramed Pharmaceuticals Inc. (“Oramed”) and certain investors with Oramed, as collateral agent, pursuant to which the Company agreed to issue to the investors senior secured convertible notes convertible into ordinary shares, no par value per share (the “Ordinary Shares”), and accompanying warrants to purchase Ordinary Shares.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jul 7, 2026 · Open the source ↗
What the evidence supports
Lifeward told the SEC (Form 8-K, Item 1.01) that it entered into a financing arrangement or sold its securities. The filing gives Jun 30, 2026 as the date of the earliest event reported.
What remains unknown
How much money will actually be raised or drawn, at what final price, and how it will be used beyond what the company stated. Stated amounts can be maximums or targets rather than money already received.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 1.01 textAs previously disclosed, Lifeward Ltd. (the “Company”) entered into a securities purchase agreement (the “Prior SPA”) with Oramed Pharmaceuticals Inc. (“Oramed”) and certain investors with Oramed, as collateral agent, pursuant to which the Company agreed to issue to the investors senior secured convertible notes convertible into ordinary shares, no par value per share (the “Ordinary Shares”), and accompanying warrants to purchase Ordinary Shares.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jul 7, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Lifeward reports entry into a material definitive agreement (Form 8-K, Item 1.01)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.